申请人:Takeda Chemical Industries, Ltd.
公开号:EP0634402A1
公开(公告)日:1995-01-18
Novel compounds represented by the formula:
wherein the ring A and the ring B each stand for an optionally substituted benzene ring;
Ar stands for an optionally substituted aryl group or an optionally substituted heterocyclic group;
Q stands for an oxygen atom or a sulfur atom;
R stands for a hydrogen atom, an optionally substituted hydrocarbon group, an optionally substituted hydroxyl group or an optionally substituted amino group;
X stands for -O- or -NR¹- wherein R¹ stands for a hydrogen atom or an optionally substituted hydrocarbon group;
Y stands for -O-, -NR²- wherein R² stands for a hydrogen atom or an optionally substituted hydrocarbon group, or a bond;
m denotes 1, 2 or 3, and
n denotes 0, 1 or 2, and salts thereof which have an excellent calcium- or substance P receptor-antagonistic activity, being useful for treating a cerebralvascular disorder in mammals such as cerebralischemia, cerebral edema and neuronal damage, their production and use.
式所代表的新型化合物:
其中环 A 和环 B 各代表一个任选取代的苯环;
Ar 代表任选取代的芳基或任选取代的杂环基团;
Q 代表氧原子或硫原子;
R 代表氢原子、任选取代的烃基、任选取代的羟基或任选取代的氨基;
X 代表-O-或-NR¹-,其中 R¹ 代表氢原子或任选取代的烃基;
Y 代表-O-、-NR²-(其中 R² 代表氢原子或任选取代的烃基)或键;
m 表示 1、2 或 3,以及
n 表示 0、1 或 2,及其盐类,它们具有优异的钙或 P 物质受体拮抗活性,可用于治疗哺乳动物的脑血管疾病,如脑缺血、脑水肿和神经元损伤。